Global Preventive Asthma Drugs Market 2015-2019

Global Preventive Asthma Drugs Market 2015-2019

  • October 2015 •
  • 81 pages •
  • Report ID: 1045443 •
  • Format: PDF
About asthma
According to the Global Initiative for Asthma, asthma is a chronic disease, which is characterized by wheezing, shortness of breath, chest tightness, and cough over a period of time. The symptoms worsen due to the increased secretion of mucus, bronchoconstriction, and thickening of the walls of the airways, resulting in difficulty in expiration. According to the American Academy of Allergy, Asthma, and Immunology, asthma is classified into four types: exercise-induced, allergic, occupational, and childhood. Also, asthma can be classified into two categories: allergic and non-allergic, as per the classification of Asthma and Allergy Foundation of America. Asthma can be managed by preventive medications, which should be administered to the patient regularly to improve his quality of life by controlling the exacerbations.

Technavio's analysts forecast the global preventive asthma drugs market to grow at a CAGR of 5.20% over the period 2014-2019.

Covered in this report
This report covers the present scenario and the growth prospects of the global preventive asthma drugs market for 2015-2019. To calculate the market size, the report considers revenue generated from the sale of the following classes of drugs used to treat asthma:
- Immunosuppressants
- Leukotriene antagonists
- Mast cell stabilizers
- Corticosteroids
- Combination of LABA/ ICS

This report includes a discussion of the market in the following three regions:
- Americas: The major countries focused in the Americas are the US, Canada, Mexico, and Brazil
- EMEA: The major countries in this region are the UK, Germany, Italy, France, Spain and Middle Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
- APAC: The major countries in this region are Japan, China, Australia, Singapore, South Korea, and India

Technavio's report, Global Preventive Asthma Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape of the global preventive asthma drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions
- Americas
- APAC
- EMEA

Key Vendors
- AstraZeneca
- F. Hoffmann-La Roche
- GlaxoSmithKline
- Merck
- Novartis

Other prominent vendors
- Abbott
- Amgen
- AptarGroup
- Biotest
- Boehringer Ingelheim
- Chiesi Farmaceutici
- Cytos
- Dainippon Sumitomo
- Medicinova
- Mylan
- Novartis
- Orchid Chemicals and Pharmaceuticals
- Pfizer
- Rottapharm Madaus
- Skyepharma
- Sosei
- Sunovion
- Teva Pharmaceutical
- Theravance
- Vectura

Key market driver
- High prevalence of asthma
- For a full, detailed list, view our report

Key market challenge
- Unknown disease etiology
- For a full, detailed list, view our report

Key market trend
- Growing popularity of combination therapies
- For a full, detailed list, view our report


Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.